Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Sitagliptin

Sitagliptin
Sitagliptin (MK0431), a new oral hypoglycemic (anti-diabetic drug), is a new dipeptidyl peptidase-4 (DPP-4) inhibitor. This enzyme-inhibiting drug is used either alone or in combination with metformin or thiazolidinedione for treatment of type 2 diabetes mellitus. The drug can competitively inhibit a protein/enzyme and DPP-4, that leads to an incremental amount of active incretins (GLP-1 and GIP), the diminished amount of release of glucagon and increased release of insulin.
Catalog No. T0242Cas No. 486460-32-6
Select Batch
Purity:99.4%
Contact us for more batch information

Resource Download

Sitagliptin

Catalog No. T0242Cas No. 486460-32-6

Sitagliptin (MK0431), a new oral hypoglycemic (anti-diabetic drug), is a new dipeptidyl peptidase-4 (DPP-4) inhibitor. This enzyme-inhibiting drug is used either alone or in combination with metformin or thiazolidinedione for treatment of type 2 diabetes mellitus. The drug can competitively inhibit a protein/enzyme and DPP-4, that leads to an incremental amount of active incretins (GLP-1 and GIP), the diminished amount of release of glucagon and increased release of insulin.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
50 mg$36In Stock
100 mg$50In Stock
200 mg$59In Stock
Bulk & Custom
Add to Cart

Related Compound Libraries of "Sitagliptin"

Product Introduction

Bioactivity
Description
Sitagliptin (MK0431), a new oral hypoglycemic (anti-diabetic drug), is a new dipeptidyl peptidase-4 (DPP-4) inhibitor. This enzyme-inhibiting drug is used either alone or in combination with metformin or thiazolidinedione for treatment of type 2 diabetes mellitus. The drug can competitively inhibit a protein/enzyme and DPP-4, that leads to an incremental amount of active incretins (GLP-1 and GIP), the diminished amount of release of glucagon and increased release of insulin.
Targets&IC50
DPP4:18 nM
In vitro
Sitagliptin phosphate demonstrates a potent inhibitory effect on dipeptidyl peptidase-4 (DPP-4), achieving an IC50 of 19 nM in Caco-2 cell extracts[1]. It also inhibits in vitro migration of isolated splenic CD4 T-cells through cAMP/PKA/Rac1 pathway activation[2]. Furthermore, sitagliptin directly enhances GLP-1 secretion from intestinal L cells via a pathway that is independent of DPP-4, but relies on protein kinase A and MEK-ERK1/2 activation. Additionally, it mitigates the impact of autoimmunity on graft survival[3].
In vivo
In vivo studies demonstrate that the ED50 (effective dose for 50% of the population) of sitagliptin phosphate, which inhibits DPP-4 activity in plasma, is estimated to be 2.3 mg/kg seven hours post-administration and 30 mg/kg twenty-four hours post-administration in freely fed Han-Wistar rats[1]. In the streptozotocin-induced type 1 diabetes mouse model, characterized by elevated plasma DPP-4 levels, sitagliptin phosphate supplementation notably reduces these levels, effectively regulating hyperglycemia and potentially enhancing islet graft longevity[4]. Moreover, pharmacokinetic profiles reveal that both plasma clearance and the volume of distribution for sitagliptin phosphate are significantly higher in rats (40-48 mL/min/kg, 7-9 L/kg) compared to dogs (9 mL/min/kg, 3 L/kg), with a half-life of 2 hours in rats versus 4 hours in dogs[5].
Kinase Assay
DPP-4 is extracted from confluent Caco-2 cells. After 5 minutes of incubation at room temperature with lysis buffer (10 mM Tris-HCl, 150 mM NaCl, 0.04 U/mL aprotinin, 0.5% Nonidet P40, pH 8.0), cells are centrifuged at 35,000 g at 4°C for 30 minutes, and the supernatant is stored at -80°C. Assays are performed by mixing 20 μL of appropriate compound dilutions with 50 μL of the substrate for the DPP-4 enzyme, H-Ala-Pro-7-amido-4-trifluoromethylcoumarin (final concentration in the assay, 100 μM) and 30 μL of the Caco-2 cell extract (diluted 1000-fold with 100 mM Tris-HCl, 100 mM NaCl, pH 7.8). Plates are incubated at room temperature for 1 hour, and fluorescence is measured at excitation/emission wavelengths of 405/535 nm using a SpectraMax GeminiXS. Dissociation kinetics of inhibitors from the DPP-4 enzyme is determined after a 1-hour preincubation of Caco-2 cell extracts with high inhibitor concentrations (30 nM for BI 1356, 3 μM for vildagliptin). The enzymatic reaction is started by adding the substrate H-Ala-Pro-7-amido-4-trifluoromethylcoumarin after a 3000-fold dilution of the preincubation mixture with assay buffer. Under these conditions, the difference in DPP-4 activity at a certain time point in the presence or absence of an inhibitor reflects the amount of this inhibitor still bound to the DPP-4 enzyme. Maximal reaction rates (fluorescence units/seconds ×1000) at 10-minute intervals are calculated using the SoftMax software of the SpectraMax and corrected for the rate of an uninhibited reaction [(vcontrol-vinhibitor)/vcontrol].
Cell Research
CD4T-cells are plated on membrane inserts in serum-free RPMI 1640, and cell migration is assayed using Transwell chambers (Corning), in the presence or absence of purified porcine kidney DPP-4 (32.1 units/mg; 100 mU/mL final concentration) and DPP-4 inhibitor (100 μM). After 1 hour, cells on the upper surface are removed mechanically, and cells that have migrated into the lower compartment are counted. The extent of migration is expressed relative to the control sample.
AliasMK0431
Chemical Properties
Molecular Weight407.31
FormulaC16H15F6N5O
Cas No.486460-32-6
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 16.67 mg/mL (40.92 mM)
H2O: <1 mg/mL (Insoluble)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.4551 mL12.2757 mL24.5513 mL122.7566 mL
5 mM0.4910 mL2.4551 mL4.9103 mL24.5513 mL
10 mM0.2455 mL1.2276 mL2.4551 mL12.2757 mL
20 mM0.1228 mL0.6138 mL1.2276 mL6.1378 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Sitagliptin | purchase Sitagliptin | Sitagliptin cost | order Sitagliptin | Sitagliptin chemical structure | Sitagliptin in vivo | Sitagliptin in vitro | Sitagliptin formula | Sitagliptin molecular weight